Financial institutions benefit from higher equity risk premiums and interest rate spreads.

Charlene Vos

2017-04-01 06:40:00 Sat ET

With the current interest rate hike, large banks and insurance companies are likely to benefit from higher equity risk premiums and interest rate spreads.

Pre-crisis U.S. banks such as Goldman and Citigroup carry financial leverage as high as 35-to-1.

Meanwhile, these banks carry financial leverage about 10-to-1.

In this golden age of finance, it is likely for banks and insurance companies to lever up with robust operating profitability to 15-to-1 in light of post-Dodd-Frank deregulation under the Trump administration.

In this respect, financial stocks are likely to experience an imminent boom in stock market valuation.

The current Trump stock market rally bring tangible benefits to bank stocks that will likely receive preferential tax treatment in the form of both lower corporate income taxes and indefinite tax holidays for offshore cash repatriation.

As the current interest rate hike attracts capital inflows from non-U.S. economic regimes, this hot money will spur macroeconomic growth, corporate investment, and technological innovation with higher wages, better high-skill jobs, and more sustainable cash dividends, share repurchases, and capital gains for the typical stock market investor.


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More
Harley Davidson plans to move its major production for European customers out of America due to European Union tariff retaliation.
Rose Prince

2018-06-21 10:42:00 Thursday ET

Harley Davidson plans to move its major production for European customers out of America due to European Union tariff retaliation.

Harley Davidson plans to move its major production for European customers out of America due to European Union tariff retaliation. European Union retaliator

+See More
Global economic uncertainty now lurks in a thick layer of mystery.
Jonah Whanau

2019-03-01 13:36:00 Friday ET

Global economic uncertainty now lurks in a thick layer of mystery.

Global economic uncertainty now lurks in a thick layer of mystery. This uncertainty arises from Sino-U.S. trade tension, Brexit fallout, monetary policy nor

+See More
Tech companies seek to serve as quasi-financial intermediaries.
Amy Hamilton

2019-03-03 10:39:00 Sunday ET

Tech companies seek to serve as quasi-financial intermediaries.

Tech companies seek to serve as quasi-financial intermediaries. Retail traders can list items for sale on eBay and then acquire these items economically on

+See More
Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018 with an incredible rags-to-riches life story.
John Fourier

2018-03-11 08:27:00 Sunday ET

Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018 with an incredible rags-to-riches life story.

At 89 years old, Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018. With a personal net worth of $35 billion, Li has an incredible ra

+See More
David Solomon succeeds Lloyd Blankfein as the new CEO of Goldman Sachs.
Fiona Sydney

2018-03-09 08:33:00 Friday ET

David Solomon succeeds Lloyd Blankfein as the new CEO of Goldman Sachs.

David Solomon succeeds Lloyd Blankfein as the new CEO of Goldman Sachs. Unlike his predecessors Lloyd Blankfein and Gary Cohn, Solomon has been an investmen

+See More
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.
Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More